ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Entos, a drug company specializing in artificial intelligence–based small-molecule discovery, has raised $54 million in series A financing, led by the investment firms Coatue Management and Catalio Capital Management. Entos’s computing technology is called OrbNet, and the San Diego–based company says it has already entered into partnerships with drug developers based on results from the technology. Its scientific advisory board includes Nobel laureate Frances Arnold.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter